Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Open-Label, Multicenter, Platform Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors

Next Previous
X
Search
Trial Profile

A Phase II, Open-Label, Multicenter, Platform Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Sep 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abemaciclib (Primary) ; Atezolizumab (Primary) ; Bevacizumab (Primary) ; Cobimetinib (Primary) ; Giredestrant (Primary) ; Inavolisib (Primary) ; Ipatasertib (Primary) ; Letrozole (Primary) ; Olaparib (Primary) ; Paclitaxel (Primary) ; Palbociclib (Primary) ; Trastuzumab emtansine (Primary) ; Goserelin; Leuprorelin; Triptorelin
  • Indications Adenocarcinoma; Carcinoma; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Acronyms BOUQUET
  • Sponsors Roche

    • Most Recent Events

    • 19 Sep 2024 Planned End Date changed from 31 Dec 2028 to 30 May 2028.
    • 19 Sep 2024 Planned primary completion date changed from 30 May 2028 to 28 Feb 2028.
    • 15 Apr 2024 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top